Q2 FY27 revenue up 28%, EBITDA up 72%, FY27 outlook upgraded
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Piramal Pharma's Q2 FY27 revenue rose 28% to Rs 2,617 crore and EBITDA jumped 72% to Rs 385 crore, lifting margin to 14.7% from 11.0%. For the half year, revenue grew 23% to Rs 4,887 crore and the net loss narrowed to Rs 64 crore. Half-year EBITDA rose 72% to Rs 669 crore. The contract manufacturing business led Q2 growth at 36%. FY27 revenue growth guidance was raised to 19-20%, with higher profitability expected.
Growth, margin gains and raised FY27 guidance are positive, but net debt of Rs 4,859 crore and the half-year loss remain concerns.